Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania:  A causal link?

Wai M. Oo a,b,c,*, Pradeep Giri a,d, Aaron de Souza b,c

1. Introduction

Guillain-Barré syndrome is an immune-mediated demyelinating neuropathy characterised by progressive symmetrical weakness of limbs and decreased or absent deep tendon reflexes (Yuki and Hartung, 2012; van Doorn, 2013). Most cases are self-resolving, but some cases experience life-threatening respiratory muscle paralysis requiring mechanical ventilation (Verboon et al., 2017). It typically occurs in the post-infectious phase following bacterial or viral illness with most cases preceded by respiratory or gastrointestinal symptoms (Willison et al., 2016; van Doorn et al., 2008). Cl. jejuni infection is associated with about one-third of the cases (McCarty and Giesecke, 2001), but other identified infectious causes include viral infections such as cytomegalovirus, hepatitis E, Epstein Barr virus and influenza A virus, and bacterial infections such as M. pneumoniae and H. influenzae (Yuki and Hartung, 2012). Although not completely understood, current studies suggest that pathogenesis is due to autoimmune destruction of the myelin sheath and/or axonal damage caused by autoantibodies leading to functional blockade of nerve conduction (Yuki and Hartung, 2012; Willison et al., 2016; van Doorn et al., 2008; Walling and Dickson, 2013).

Although rare, several studies have explored a possible association of GBS to vaccination, notably the increased risk of GBS with H1N1 influenza (Swine Flu) vaccination in 1976 (Schonberger et al., 1979). The vaccination campaign against ‘Swine Flu’ was halted after a spike in cases of GBS was noted, with an incidence as high as 1 per 100,000 vaccinations (Junn et al., 2001). Other studies explored the occurrence of GBS during influenza vaccination campaigns in 1990–2005 but suggested a relatively low risk associated with influenza vaccination (Lehmann et al., 2010; Stowe et al., 2009).

Herein, we report four cases of inflammatory demyelinating polyneuropathy presenting to the same hospital in northern Tasmania 1–3 weeks following ChAdOx1 nCoV-19 vaccination (AstraZeneca vaccine, AZ).

2. Cases

Over the course of six weeks, four individuals presented with inflammatory demyelinating Polyneuropathy (IDP), one with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and three with Inflammatory Demyelinating Polyneuropathy (CIDP) and three with Chronic inflammatory demyelinating polyneuropathy (CIDP).
years (Table 1). All of them developed lower back pain followed by progressive ascending paraesthesia, predominantly proximal para-paresis or quadriparepsis and areflexia. Two developed facial weakness. Two progressed to respiratory failure requiring mechanical ventilation.

In all patients, investigations revealed albuminocytologic dissociation in the CSF, and no potentially pathogenic organism was isolated. Electrophysiological confirmation of a demyelinating pathology consistent with IDP was obtained in all patients. All four were treated with IVIG (Intravenous immune Globulin). Three are currently inpatients at the hospital, one in ICU, one in rehabilitation, and one in the general medical ward. The patient with CIDP was safely discharged home.

2.1. Case 1

A 65-year-old female with no significant past medical history, in

Table 1 Description of 4 cases of COVID-19.

| Demographics | Co-morbidities | Vaccine | Onset of symptoms in relation to vaccination | Other vaccines | Type of IDP | Clinical presentation | CSF | NCS |
|--------------|----------------|---------|--------------------------------------------|----------------|-------------|----------------------|-----|-----|
| Age: 66      | None           | AZ      | Onset: 1 week post 1st dose                | influenza vaccine | GBS         | Nadir: at 2 weeks    | Albuminocytologic dissociation | Absent ulnar and sural sensory responses with slowed median sensory and motor NCV, prolonged distal motor latencies, absent F-waves. |
| Sex: Female  | Ethnicity:     |         |                                            |                |             | -Lower back pain     | Protein: 0.70                  | WCC: 0 | RBC: 0 |
|              | Caucasian      |         |                                            |                |             | -Bifacial weakness   | WCC: 5                        | RBS: 95 | Viral panel: negative |
|              |                |         |                                            |                |             | -Dysphagia           | Proteins: 2.51 g/L              | Viral panel: negative |
|              |                |         |                                            |                |             | -Diplopia            | Culture: no growth             | Culture – no growth |
|              |                |         |                                            |                |             | -Respiratory failure  | -Progressive ascending upper limb sensorimotor deficit |
|              |                |         |                                            |                |             | -Areflexia           | Albuminocytologic dissociation |
| Age: 72      | Idiopathic neuropathy | AZ      | Onset: 3 weeks post 1st dose               | influenza vaccine | CIDP         | Nadir: at 5 weeks    | Albuminocytologic dissociation |
| Sex: Male    | Ethnicity:     |         |                                            |                |             | -Progressive ascending lower limb sensorimotor involvement | Protein: 0.55 | WCC: 0 | RBC: 0 | Viral Panel: not tested |
|              | Caucasian      |         |                                            |                |             | -Upper limb sensorimotor deficit | Culture: no growth |
|              |                |         |                                            |                |             | -Areflexia            | Prolonged distal motor, and F- minimum latencies, slowed motor NCV. |
| Age: 66      | Renal Cell Carcinoma | AZ      | Onset: 3 weeks post 1st dose               | influenza vaccine | GBS         | Nadir: at 4 weeks    | Albuminocytologic dissociation |
| Sex: Male    | Ethnicity:     |         |                                            |                |             | -Lower back pain     | Protein: 1.5                  | WCC: 0 | RBC: 0 | Viral Panel: negative |
|              | Caucasian      |         |                                            |                |             | -Progressive ascending sensorimotor involvement | Culture: No growth |
|              |                |         |                                            |                |             | -Proximal lower limb weakness | Absent median sensory responses with sural sparing, absent peroneal and tibial motor responses, prolonged median distal motor, and F- minimum latencies with slowed motor NCV. |

* AZ = Oxford/AstraZeneca ChAdOx1 nCoV-19 COVID-19 vaccine, GBS = Guillain Barre Syndrome, CIDP = Chronic inflammatory demyelinating neuropathy, NCV = nerve conduction velocity.
areflexic quadriparesis most severe in the proximal lower limbs. Her sensory deficit was symmetrical and length dependent. Two days following admission, she developed respiratory distress, resulting in ICU admission with intubation.

Her CSF showed albuminocytologic dissociation and a viral panel was negative. Electrophysiology confirmed a demyelinating polyneuropathy consistent with GBS. Antiganglioside antibodies (anti-GM1, anti-GQ1b), HIV, and vasculitis screen were negative. Imaging of the neuraxis was normal aside from a few nonspecific white matter T2-hyperintense lesions. She improved remarkably after a course of IVIg. She was extubated and is currently in a rehabilitation centre.

2.3. Case 3

A 72-year-old male developed ascending lower limb weakness and sensory changes, on the background of pre-existing peripheral neuropathy with stable distal sensory loss in the legs and feet for over three years.

Three weeks after his first dose of AZ vaccination, he observed weakness in his left foot which eventually evolved into symmetric proximal lower limb weakness. These symptoms antedated a subsequent influenza vaccination. He then presented to the emergency department six weeks after onset with worsening lower limb weakness impairing ambulation. His pre-existing sensory symptoms also progressed proximally to involve his thighs.

On examination, he had a predominantly proximal quadriparesis with loss of vibration, proprioception, and pinprick sensation in both hands and up to mid-thigh in lower limbs. His CSF showed albuminocytologic dissociation. A Nerve conduction study revealed a prolonged distal motor latency with reduced nerve conduction velocity in keeping with demyelinating disease.

The temporal course of the illness was consistent with CIDP. He improved clinically after a course of IVIg and is currently ambulant without aid, showing continuing improvement with rehabilitation.

2.4. Case 4

A 66-year-old male developed lower back pain and bilateral symmetrical distal paraesthesia in hands and feet, three weeks post-AZ vaccination and eight weeks after an influenza vaccine. He developed predominantly proximal paraparesis one week after ascending paraesthesia, with a subsequent right infranuclear facial palsy over the course of 3 weeks from the onset of symptoms.

On examination, he had proximal paraparesis, prominent right facial lower motor neuron weakness, and areflexia.

His CSF showed albuminocytologic dissociation and nerve conduction study was in keeping with the demyelinating nature of GBS. A CSF viral panel was negative. IVIg effectively halted the progression of the disease. He is currently an inpatient for rehabilitation and other medical issues.

3. Discussion

Since late 2019, the emergence of the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented an unprecedented global challenge (Rothan and Byrareddy, 2020; Lu et al., 2021). Multiple vaccines have been developed against SARS-CoV-2 and at the time of writing, 20 vaccines are approved and being used globally with over 4 billion doses administered to date (COVID-19 Map, 2021). All vaccines against COVID-19 were developed rapidly and rare adverse outcomes related to these vaccines are still being documented as the global rollout continues (Mullard, 2020; Kaur et al., 2021). Multiple case reports describe a likely causal association between COVID-19 and GBS (Ray et al., 2021; Montalvan et al., 2020). This raises the possibility that COVID-19 vaccination may also cause GBS. Indeed, 18 cases of ChAdOx1 nCoV-19 vaccine-related GBS have been reported across 6 published studies from UK, Qatar, and India (Hasan et al., 2021; Patel et al., 2021; Azam et al., 2021; Razok et al., 2021; Maramatoom et al., 2021; Allen et al., 2021) (Table 2). Our four cases lend further weight to the likely causal link between COVID-19 vaccine AZ and GBS.

GBS is characterised by varying combination of limb weakness, autonomic dysfunction, and cranial nerve involvement (Yuki and Hartung, 2012), usually within one or two weeks of immune activation with peak severity at about four weeks (Fokke et al., 2014). The temporal relationship of receipt of COVID-19 vaccination in our cases fits this timeframe. All our cases demonstrated the characteristic CSF features of albuminocytological dissociation and demyelination on electrophysiological studies (van Doorn, 2013; Fokke et al., 2014).

The annual incidence of GBS varies between 1.1 and 2.66 cases per 100,000 (McGrogan et al., 2009). In a binational study conducted in Australia and New Zealand, the incidence of GBS was 5.4 cases per million population every year (Ancona et al., 2019). Tasmania has a population of 541,071 and the hospital serves a population of 110,472. Therefore 6 cases over the short timeframe, 4 cases reported above and 2 other cases unrelated to vaccine, equates to a rate of 5.4 per 100,000 and is highly unlikely to have occurred as a cluster by coincidence.

CIDP is a common chronic neuropathy characterised by relapsing and progressive weakness (Mathey et al., 2015). Clinical features include peripheral and distal neuropathy involving motor and sensory deficits that usually develop within eight weeks (Dalakas, 2011). Usually responding to immunotherapies, the demyelinating process in CIDP involves spinal nerve roots and proximal nerves. Although the immunopathological mechanisms of the disease process are similar to GBS, the symptoms in CIDP usually peak within six to eight weeks with a fluctuating course depending on the response to treatment (Dalakas, 2011).

The exact mechanism of the immune response linked to the pathogenesis of GBS is still not clear (Yuki and Hartung, 2012; van Doorn et al., 2008). Immune-mediated damage of myelin sheath and Schwann-cell have been noted in acute inflammatory demyelinating polyneuropathy and the axolemma is directly involved in motor axonal neuropathy (Willison et al., 2016). In GBS, over 50% of patients develop antiganglioside antibodies (van Doorn et al., 2008). Molecular mimicry between microbial proteins and nerve cell surface has been one of the suggested mechanisms of autoreactivity of the immune system leading to axonal damage (Iadecola et al., 2020). Other studies postulate mechanisms including humoral or T-cell mediated antibodies specifically targeting peripheral nerve gangliosides leading to neurological deficits and specific types of GBS subtypes (Yuki and Hartung, 2012; Willison et al., 2016; van Doorn et al., 2008; Walling and Dickson, 2013).

Although COVID-19 is predominantly a respiratory illness, it can affect multiple organs including the nervous system (Montalvan et al., 2020; Song et al., 2020). In-vivo studies in mice and using human pluripotent stem cells have shown that SARS-CoV-2 can cause direct neuronal damage through the ACE2 dependent pathway (Song et al., 2020). Some studies have suggested a possible association between COVID-19 and GBS (Caress et al., 2020) whereby binding of SARS-CoV-2 spike proteins to ACE2 receptors and gangliosides leads to the formation of antiganglioside antibodies and GBS during COVID-19 (van der Meché et al., 2001). This mechanism has also been described for C. jejuni and Zika associated GBS (28).

Vaccines to prevent COVID-19 have been developed at a rapid pace (Mullard, 2020). More than 280 vaccines are in different phases of development including >100 in various stages of clinical trials (Mao et al., 2021). AZ vaccine consists of a chimpanzee adenovirus vector encoding the spike protein of SARS-CoV-2 (Madhi et al., 2021). Tens of millions of doses have been administered worldwide across more than 170 countries. The most likely mechanism of GBS induction is that antibodies to the S protein cross-react with gangliosides, forming autoantibodies leading to myelin damage.

Similar to earlier reports from Asia and Europe, our patients...
 developed symptoms within three weeks after the first dose of AstraZeneca vaccine. One of our patients had bifacial weakness, which was also reported in twelve of the internationally reported cases. Two of our cases developed respiratory failure requiring ICU admission for ventilatory support, while one had an acute exacerbation of CIDP. Our diagnosis of GBS and CIDP was based on clinical features, CSF results and NCS results with Level 1 diagnostic certainty according to the Brighton criteria (van der Meche et al., 2001; Poser, 1981; Asbury and Cornblath, 1990).

In conclusion, an increasing number of case reports highlight the occurrence of inflammatory demyelinating polyneuropathy following administration of the AstraZeneca COVID-19 viral vector vaccine, emphasizing the need for vigilance regarding this specific adverse effect. Most reported cases involve a variant of GBS with bifacial weakness and respiratory failure. A potential link between GBS and AstraZeneca vaccine cannot be excluded at this time and indeed seems highly likely. Healthcare professionals are urged to report GBS post COVID-19 vaccination since accurate numbers will help us further confirm the potential causal link.

### Consent

Informed verbal consent was obtained from all the subjects.

### Declaration of Competing Interest

There is no conflict of interest to report.

### Acknowledgement

Professor Katie Flanagan, Head, Department of Infectious Diseases, Launceston General Hospital; Tasmania Vaccine Trial Centre, Clifford Craig Foundation, Launceston General Hospital; School of Medicine, University of Tasmania, Launceston, Tasmania.

### References

Allen, C.M., Ramsamy, S., Tarr, A.W., Tighe, P.J., Irving, W.L., Tanasiecu, R., Evans, J.R., 2021. Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann. Neurol. 90, 315–318.

Ancona, P., Bailey, M., Bellomo, R., 2018. Characteristics, incidence, and outcome of patients admitted to intensive care unit with Guillain-Barré syndrome in Australia and New Zealand. J. Crit. Care 45, 58–64.

Asbury, A.K., Cornblath, D.R., 1990. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 27 (Suppl), S21–S24.

Azam, S., Khalil, A., Taha, A., 2021. Guillain-Barré syndrome in a 67-year-old male post COVID-19 vaccination (Astra Zeneca). Am. J. Med. Case Rep. 9, 424–427.

Carees, J.B., Castoro, R.J., Simmons, Z., Seela, S.N., Lewis, R.A., Ahlawat, A., Narayanaswami, P., 2020. COVID-19-associated Guillain Barre syndrome: the early pandemic experience. Muscle Nerve 62, 485–491.

Dalakas, M.C., 2011. Advances in the diagnosis, pathogenesis, and treatment of CIDP. Nat. Rev. Neurol. 7, 507–517.

Fokke, C., Van Den Berg, B., Drenthen, J., Walgaard, C., van Doorn, P.A., Jacobs, B.C., 2014. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 137, 53–43.

Hasan, T., Khan, M., Khan, F., Hamza, G., 2021. Case of Guillain-Barré syndrome following COVID-19 vaccine. BMJ Case Rep. 14.

Iadecola, C., Anrather, J., Kavel, H., 2020. Effects of COVID-19 on the nervous system. Cell 183, 16–27 e1.

COVID-19 Map, 2021. Johns Hopkins Coronavirus Resource Center (jhu.edu). Available: https://coronavirus.jhu.edu/map.html.

Kaur, R.J., Dutta, S., Bhadrwaj, P., Charan, J., Dhangra, S., Mitra, P., Singh, K., Yadav, D., Sharma, P., Mitra, S., 2021. Adverse events reported from COVID-19 vaccine trials: a systematic review. Ind. J. Clin. Biochem. IJCB 1, 1–9.

Lunn, M.P., Cornblath, D.R., Jacobs, B.C., Quarel, L., van Doorn, P.A., Hughes, R.A., Willison, H.J., 2021. COVID-19 vaccine and Guillain-Barré syndrome: let’s not leap to associations. Brain 144, 357–360.

Maddi, S.A., Balillas, V., Cutland, C.L., Voseve, M., Koen, A.L., Fairlie, L., Padayachee, S., Patel, F., Pillay, S., Rhead, S., Rodel, H., Roodt, L., Tassier, C., Teggally, H., Tomo, W., van Eck, S., Wibmer, C.K., Durham, N.M., Kelly, E.J., Villafane, T.L., Gilbert, S., Pollard, A.J., de Oliveira, T., Moore, P.L., Siga, A., Izu, A., 2021. Guillain-Barré syndrome associated with COVID-19 vaccination. Lancet Infect. Dis. 21, 435–442.
2021. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New Engl. J. Med. 384, 1885–1898.
Mao, Q., Xu, M., He, Q., Li, C., Meng, S., Wang, Y., Cui, B., Liang, Z., Wang, J., 2021. COVID-19 vaccines: progress and understanding on quality control and evaluation. Signal Transduct. Targeted Therapy 6, 199.
Marramattou, B.V., Krishnan, P., Paul, R., Padmanathan, S., Cherukudal Vishnu Nampoothiri, S., Syed, A.A., Mangat, H.S., 2021. Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine. Ann. Neurol. 90, 312–314.
Mathey, E.K., Park, S.B., Hughes, R.A., Pollard, J.D., Armati, P.J., Barnett, M.H., Taylor, B.V., Dyck, P.J., Kiernan, M.C., Lin, C.S., 2015. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J. Neurol. Neurosurg. Psychiatry 86, 973–985.
McCarthy, N., Giesecke, J., 2001. Incidence of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 32, 150–163.
Montalvan, V., Lee, J., Bueso, T., De Toledo, J., Rivas, K., 2020. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clin. Neurol. Neurosurg. 194, 105921.
Mullard, A., 2020. COVID-19 vaccine development pipeline gears up. Lancet 395, 1751–1752.
Patel, S.U., Khurram, R., Lakhani, A., Quirk, B., 2021. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep. 14, e242956.
Poser, C.M., 1981. Criteria for the diagnosis of the Guillain-Barré syndrome. A critique of the NINCDS guidelines. J. Neurol. Sci. 52, 191–199.
Ray, S.T.J., Abdel-Mannan, O., Sa, M., Fuller, C., Wood, G.K., Pyden, K., Yoong, M., McCullagh, H., Scott, D., Menahon, M., Thomas, N., Taylor, M., Illingsworth, M., McCrea, N., Davies, V., Whitehouse, W., Zuberi, S., Guthrie, K., Wassmer, E., Shah, N., Baker, M.R., Tivary, S., Tan, H.J., Varma, U., Ram, D., Avula, S., Enright, N., Hassell, J., Ross Russell, A.L., Kumar, R., Mulholland, R.E., Pett, S., Galea, I., Thomas, R.H., Lim, M., Hacohen, Y., Solomon, T., Griffiths, M.J., Michael, B.D., Kneen, R., 2021. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc. Health 5 (9), 631–641.
Razok, A., Shams, A., Almeer, A., Zahid, M., 2021. Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar. Ann. Med. Surg. (Lond.) 67, 102540.
Rothan, H.A., Byrareddy, S.N., 2020. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun. 109, 102433.
Schonberger, L.B., Bregman, D.J., Sullivan-Bolyai, J.Z., Keenlyside, R.A., Ziegler, D.W., Retali, H.F., Eddins, D.L., Bryan, J.A., 1979. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am. J. Epidemiol. 110, 105–123.
Song, E., Zhang, C., Israelow, B., Lu, P., Weizman, O.-E., Liu, F., Dai, Y., Szigi et-Buck, K., Yasumoto, Y., Wang, G., Castaldi, C., Helkite, J., Ng, E., Wheeler, J., Alfajaro, M.M., Fontes, B., Ravindra, N.G., Van Dijk, D., Mane, S., Gunel, M., Ring, A., Wilen, C.B., Horvath, T.L., Louvi, A., Farhadian, S.P., Bilguvar, K., Iwanaki, A., 2020. Neuroinvasive potential of SARS-CoV-2 revealed in a human brain organoid model. bioRxiv. https://doi.org/10.1101/2020.06.25.169946.
Stowe, J., Andrews, N., Wiser, L., Miller, E., 2009. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am. J. Epidemiol. 169, 382–388.
van der Meché, F.G.A., van Doorn, P.A., Mealstee, J., Jennekens, F.G.I., 2001. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur. Neurol. 45, 123–139.
van Doorn, P.A., 2013. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). Presse Med. 42, e193–e201.
van Doorn, P.A., Ruts, L., Jacobs, B.C., 2008. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 7, 939–950.
Verboom, C., van Doorn, P.A., Jacobs, B.C., 2017. Treatment dilemmas in Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry 88, 346–352.
Wallig, A.D., Dickson, G., 2013. Guillain-Barré syndrome. Am. Fam. Physician 87, 191–197.
Willison, H.J., Jacobs, B.C., van Doorn, P.A., 2016. Guillain-Barré syndrome. Lancet 388, 717–727.
Yuki, N., Hartung, H.P., 2012. Guillain-Barré syndrome. N. Engl. J. Med. 366, 2594–2594.